0001415889-24-001313.txt : 20240117
0001415889-24-001313.hdr.sgml : 20240117
20240117164828
ACCESSION NUMBER: 0001415889-24-001313
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240116
FILED AS OF DATE: 20240117
DATE AS OF CHANGE: 20240117
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Thye Dirk
CENTRAL INDEX KEY: 0001638945
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38890
FILM NUMBER: 24539052
MAIL ADDRESS:
STREET 1: 6310 NANCY RIDGE DRIVE
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Quince Therapeutics, Inc.
CENTRAL INDEX KEY: 0001662774
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 901024039
STATE OF INCORPORATION: CA
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 611 GATEWAY BLVD., SUITE 273
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: 415-910-5717
MAIL ADDRESS:
STREET 1: 611 GATEWAY BLVD., SUITE 273
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
FORMER COMPANY:
FORMER CONFORMED NAME: Cortexyme, Inc.
DATE OF NAME CHANGE: 20160104
4
1
form4-01172024_090120.xml
X0508
4
2024-01-16
0001662774
Quince Therapeutics, Inc.
QNCX
0001638945
Thye Dirk
C/O QUINCE THERAPEUTICS, INC.
601 GATEWAY BLVD, #1250
SOUTH SAN FRANCISCO
CA
94080
true
true
false
false
CHIEF EXECUTIVE OFFICER
0
Common Stock
2024-01-16
4
M
0
90531
0.55
A
539442
D
Common Stock
2024-01-16
4
M
0
149999
0.94
A
689441
D
Employee Stock Option (right to buy)
0.55
2024-01-16
4
M
0
90531
0
D
2022-03-27
Common Stock
90531
115860
D
Employee Stock Option (right to buy)
0.94
2024-01-16
4
M
0
149999
0
D
2033-01-31
Common Stock
149999
450001
D
The shares subject to the option shall vest over a four-year period, with 25% of the shares subject to the option vesting on the first anniversary of the vesting commencement date and the remainder vesting in 36 equal monthly installments over the following three years.
The shares subject to this option shall vest in equal monthly installments, at a rate of 1/48th of the total number of shares on each monthly anniversary of the vesting commencement date of January 1, 2023, such that the total number of shares shall be fully vested on the four-year anniversary of the vesting commencement date.
/s/ Dirk Thye
2024-01-17